Cheryl L. Turnbull Elected to Board of Directors of Quick-Med Technologies, Inc. 

Gainesville, Florida, January 9, 2006 - Quick-Med Technologies, Inc. (OTC Bulletin Board: QMDT) (“Quick-Med Technologies” or “QMT”) is pleased to announce that Cheryl L. Turnbull has been elected to our board of directors effective January 19, 2006.

Ms. Turnbull has more than twenty years of experience encompassing private equity investments, mergers and acquisitions, corporate finance, and strategic advisory services. Ms. Turnbull is a Special Limited Partner at Phronesis Partners LP, a Columbus, Ohio-based hedge fund, since January 2005. From 1996 to 2003, Ms. Turnbull was responsible for the mezzanine investment functions of various units of Banc One Corporation. Prior to that time, Ms. Turnbull was a Managing Director of Aston Limited Partners, LP, a financial restructuring firm between 1992 and 1995. Between 1990 and 1991, Ms. Turnbull was Vice President of Prudential Bache Interfunding, a private equity fund and, from 1987 to 1990, an Associate in the Mergers & Acquisitions department of Prudential Securities. Ms. Turnbull began her career as an Analyst in the Corporate Finance Division at Continental Illinois National Bank & Trust Co.

“Cheryl is a key addition to our board of directors, " said Michael R. Granito, Chairman of Quick-Med Technologies. "Her private equity and overall corporate experience are very strong and will assist in guiding our strategy and execution.  

Ms. Turnbull remarked, "I am delighted to be joining the accomplished members of Quick-Med Technologies’ board. NIMBUS™ and MultiStat™ are state of the art technologies, and can provide solutions to major hurdles within the healthcare and consumer markets. I look forward to working with the company team to add value to Quick-Med Technologies’ operations." added Ms. Turnbull.

Ms. Turnbull received her Master of Management in Finance and International Business from the J.L. Kellogg Graduate School of Management at Northwestern University and is a graduate of Miami University of Ohio.

With her election, Quick-Med Technologies directors number eight.

Additional information regarding the election of Ms. Turnbull can be found in the Company's Form 8-K filed on January 4, 2006 with the Securities and Exchange Commission and the Company's Definitive Information Statement on Schedule 14C filed on December 30, 2005.

About Quick-Med Technologies, Inc.
Quick-Med Technologies is a life sciences company focused in developing proprietary, broad-based technologies for consumer, industrial, and healthcare use, as well as for advanced military and civilian medical applications. The Company¹s two core products under development are (1) MultiStat™, a family of advanced compounds shown to be effective in broad-based skin therapy applications, and (2) NIMBUS™, a family of advanced polymers that can be used in a wide range of applications from advanced wound care to wood preservatives. Quick-Med Technologies is listed under the symbol "QMDT" on the OTC Bulletin Board. For additional information, visit Quick-Med Technologies¹ website: www.quickmedtech.com or email: info@quickmed-technologies.com

For additional further information, please contact QMT:

David S. Lerner -- President
Phone : (561) 750-4202
Email: dlerner@quickmed-technologies.com

Natasha A. Sorobey -- Corporate & Investor Relations (Canada)
Phone: (403) 203-4748
Email: nsorobey@quickmed-technologies.com

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology is intended to identify forward-looking statements involve risks and uncertainties, including launch and approval of the potential products described herein and the Company¹s results of operations. The Company is also subject to other risks as detailed from time-to-time in the Company¹s SEC filings.